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,e main treatment available for idiopathic macular holes is represented by pars plana vitrectomy with internal limiting
membrane peeling. However, late-stage macular holes are affected by a higher risk of surgical failure. Although adjuvant
techniques can be employed, a satisfactory functional recovery is difficult to achieve in refractory macular holes. Given their
neuroprotective and antiapoptotic properties, mesenchymal stem cells (MSCs) may represent an appealing approach to treat these
extreme cases.,e purpose of this review is to highlight the findings regarding healing mechanisms exerted by mesenchymal stem
cells and preliminary application in cases of refractory macular holes. When compared with MSCs, MSC-derived exosomes may
represent a feasible alternative, given their reduced risk of undesired proliferation and easiness of use.
1. Introduction
A macular hole is an anatomic gap in the retina occurring at
the level of the fovea. ,e majority of macular holes is id-
iopathic, although they can be associated with highly myopic
eyes or ocular trauma, especially in the elderly [1].
,e general prevalence of full-thickness idiopathic
macular holes found in the Beaver Dam Study is 0.3%, with
rates increasing to 0.8% in people with 75 or more years of
age [2]. ,e genesis of macular holes is supposed to be
promoted by vitreous tractions or due to epiretinal mem-
branes at the level of the fovea.
Occasionally, macular holes are associated with retinal
detachments, leading to severe visual impairment, especially
in elderly people with elevated myopia and in the presence of
a posterior staphyloma [3, 4].
,e typical progression of macular holes is characterized
by a series of stages (reported by a biomicroscopic analysis
by Gass) over a period of weeks, featuring retinal defects
which in severe cases involve the macular region in all its
thickness [5]. In the later years, optical coherence tomog-
raphy (OCT) has become a useful method to confirm di-
agnosis and to better define the staging of macular holes. If
left untreated, full-thickness macular holes lead to a poor
visual prognosis, with visual acuity of 20/100 in more than
50% of all cases [6–10].
As a treatment for macular holes, Kelly et al. introduced
in 1991 the use of pars plana vitrectomy, with removal of
epiretinal membranes and introduction of long-acting gas
tamponades [11]. Internal membrane peeling has been
proposed by Eckardt et al. to further improve anatomical
closure rates [12].
Other several advances in this surgical field allowedmore
satisfactory outcomes with a 98% closure rate of early-onset
macular holes [13]. However, treatment of large (>400 μm)
and late-diagnosed macular holes (>6 months) are affected
by low success rates [14], particularly in highly myopic eyes
[15]. In fact, size and stage of macular holes, duration of
symptoms, and preoperative visual acuity have been re-
ported as prognostic factors [16]. Moreover, a retrospective
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chart review by Kim et al. concluded that large basal hole
diameter and thin choroid are associated with poorer visual
outcomes [17].
As of today, the goal of the surgical procedure focuses on
the resolution of vitreal or epiretinal tangential tractions on
the central retina and macular hole’s margins, achieving its
closure with good anatomical results inmore than 90% of eyes
with full-thickness macular holes [18–20]. Even if a review by
Parravano et al. concluded that vitrectomy is effective in
improving visual acuity and in achieving hole closure [21],
surgical closure rates are relatively low in complex cases, such
as large macular holes, myopic macular holes or refractory
holes after the first surgery [15, 22–24]. Novel techniques have
been introduced to improve anatomical and visual outcomes
in complicated cases [25–29]. ,ese techniques include
outpatient fluid-gas exchange, the inverted internal limiting
membrane (ILM) flap technique, ILM fragment trans-
plantation, and the use of human autologous serum, platelet
concentrate, transforming growth factor-beta 2, and heavy
silicone oil endotamponades [26, 30–40]. Inverted ILM flap
techniques may facilitate the proliferation of glial cells, which
then fill the hole and facilitate its closure and are currently
employed as a treatment of choice for macular holes in pa-
tients with severe myopia and posterior staphylomas. How-
ever, even if good anatomical outcomes (with successful
macular hole closure) are achieved, functional recovery and
regeneration of the retina are difficult to obtain, especially in
case of late stages of the disease.
Retinal degenerative diseases can be characterized by loss
of cellular elements, such as retinal ganglion cells (RGC),
retinal pigment epithelium (RPE) cells, and photoreceptors,
and the following visual impairment is typically irreversible,
since retinal cells lack self-repair capability. Several cell-
based treatments have been proposed and evaluated to
overcome these limits.
Cell therapy represents an appealing alternative to obtain
regeneration of damaged retina, potentially improving
functional outcomes also in surgery of macular hole. Trans-
plantation of retinal cells has been considered as a potential
treatment for retinal degenerative diseases, particularly in late
stages associated with severe cell damage. ,is approach aims
at replacing lost retinal cells using stem cells, progenitor cells,
and mature neural retinal cells with potential applications in a
wide range of retinal degenerative conditions.
,e purpose of this review is to highlight perspectives of
cell-based treatment for refractory macular holes, focusing
particularly on the current evidence regarding the appli-
cation of autologous mesenchymal stem cells (MSCs) since
they overcome the ethical and safety problems of embryonic
and induced pluripotent stem cells (ESCs and iPSCs, re-
spectively). In addition, mesenchymal stem cells can be
easily extracted from different human tissues and possess
neuroprotective and immunomodulatory properties.
2. Hints of Cell Therapy for
Retinal Degenerations
Appealing anatomic and functional outcomes have been
reported in animal models of retinal degeneration by various
study groups evaluating the transplant of RPE cells, retinal
progenitor cells, photoreceptor precursors, or full-thickness
retinal sheets [41–44]. However, integration into the re-
ceiving retina and functional recovery still represent major
obstacles for successful transplant. Submacular trans-
plantation of autologous RPE, retrieved from the peripheral
retina, has led to visual acuity improvements in patients
affected by macular degeneration [45–48]. However, since
ocular autologous cell sources are limited, a treatment based
on stem cells seems more feasible, given their potentially
unlimited proliferative properties.
In fact, it is possible to obtain a virtually unlimited source
of different retinal cells (RPE cells, ganglion cells, and
photoreceptors) from the expansion of pluripotent stem
cells, both embryonic and iPSCs, as shown in numerous
studies [49–53].
Several stem-cell types can differentiate into photore-
ceptors in preclinical models of human retinal degenerative
disease, including bone marrow-derived hematopoietic stem
cells, bone marrow-derived MSCs, neural progenitor cells
(NPCs), and forebrain-derived progenitor cells [54]. Carr
et al. [55] evaluated the injection of human iPSC-derived
RPE transplants (iPSC-RPE) in murine models of retinal
degeneration, with protective effects on photoreceptors and
better optokinetic responses in treated rats when compared
with the control group. Finally, photoreceptor rescue effects
of RPE derived from iPSC have been observed in retinal
degeneration in mice [56].
3. Mesenchymal Stem Cells for Retinal Diseases
Mesenchymal stem cells possess the ability of self-renewal
and unlimited differentiation. Moreover, it is possible to
retrieve MSCs from several human tissues (bone marrow,
dental pulp, adipose tissue, etc.). Given their well-known
properties and the possibility to isolate MSCs with ease, this
cell type represents a promising candidate for the treatment
of retinal degenerative diseases [57]. In fact, MSCs feature a
good proliferative potential with proven neuroprotective
effects and reduced immunogenicity [58]. Furthermore,
MSCs and MSC-derived exosomes (MSC-Exos) have been
successfully tested for the treatment of retinal inflammation
[59–62], injury [63], and degeneration [64, 65].
MSCs derived from both bone marrow and adipose
tissue have been injected into the subretinal space of animal
models of retinal degeneration with significant improve-
ments in terms of visual function and RGC density, although
for a short period [66–68]. Other studies indicated that bone
marrow-derived MSCs (BMMSCs) might differentiate into
photoreceptors cells after their introduction in the subretinal
cavity, as observed in rats with hereditary retinal de-
generation [69]. Moreover, transplantation of BMMSCs in
animal models of retinitis pigmentosa led to preservation of
outer nuclear layer cells, with prolonged photoreceptor
survival [70]. Our group had performed preliminary eval-
uations of MSCs intravitreal injections in rat models,
highlighting the ability of MSCs to survive, migrate, and
integrate at the level of the ganglion cell layer, which im-
proved in case of retinal ischemia (Figure 1) [71].
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It is indicated that MSCs can express a variety of factors
which could protect the injured retina, such as NGF, CNTF,
BDNF, bFGF, NTFs, and IGF1 [67, 72, 73]. ,e mechanisms
which these effects are based on have been extensively de-
scribed in the literature [74, 75]. Moreover, it has been
reported that MSCs secrete also factors modulating perfu-
sion and neovascularization in ischemic retina [76, 77].
,e intravitreal use of CD34 + BMMSCs in patients with
age-related macular degeneration has been evaluated in
three phase I clinical trials, with improved visual acuity
over a 12-month follow-up (NCT01518127, NCT01068561,
and NCT01518842) [78, 79]. In a phase II clinical trial
(NCT01560715), a quality-of-life improvement in patients
affected by retinitis pigmentosa was observed, although not
sustained at 12 months after MSCs injection [80–82].
However, in a study employing CD34 +BMSCs intra-
vitreal injections (with 3.4×106 cells in a 0.1ml suspension),
no improvement in visual function was observed in 6 pa-
tients affected by AMD, even if no complications occurred
[79, 82]. In a study by Weiss et al., patients with different
retinal diseases received varied BMMSCs administration
methods (retrobulbar, subtenonian, intravitreal, intraoptic
nerve, subretinal, and intravenous) in accordance with
different ocular diseases (NCT01920867), with improve-
ments in terms of visual acuity and visual field parameters
[83–86].
Severe complications and vision loss, related probably to
stem-cell preparation, have been observed in a clinical trial
adopting adipose-derived MSCs (NCT02024269), leading to
the withdrawal of the study [87]. ,is discrepancy in out-
comes between BMMSCs and adipose-derivedMSCs may be
due to different quantity and preparation of injectable so-
lution, given the significant differences among the con-
ducted trials.
4. Mesenchymal Stem Cells for Macular Holes:
Current Evidence
Currently, little evidence is present in the literature re-
garding the application of mesenchymal stem cells for the
treatment of macular holes, in both animal models and
humans. In order to assess the feasibility of cell therapy in
the treatment of macular holes, Hara et al. and Yamana et al.
first applied human adipose-derived MSCs in rabbit models
of retinal hole [88, 89], with restoration of anatomic
integrity.
Encouraged by these positive findings, Xuqian et al.
injected in vitro adipose-derived MSC cultures into rabbits
with retinal holes undergoing vitrectomy, evaluating the
effects with optical coherence tomography and immuno-
histochemical analysis. OCT images of treated eyes day
showed reattachment of the everted hole edges at the second
day after surgery with onset of healing tissue at the 4th
postoperative day, in contrast with control eyes in which
healing was delayed till the 32nd postoperative day. In ad-
dition, final retinal thickness was significantly greater in
treated eyes (with values similar to normal retina) in
comparison with control eyes (p � 0.001), with more evi-
dent differences at early postoperative time [90].
To confirm the effects of adipose-derived MSCs, addi-
tional cell injections were performed in refractory retinal
holes after surgery in the control group, with clear obser-
vation of a healing process similar to the one occurred in the
treatment group.
,e histological analysis by Xuqian et al. confirmed that
healing tissue cells were different in the retinal holes of the
treated group compared to the control group. In fact, control
eyes presented a proliferation of collagenous fibrotic tissue,
while the retina of treated eyes featured mesenchymal tissue
with photoreceptor- and bipolar-like cells. However, it was
observed that these cells were not originated from injected
MSCs since the transplanted donor cells did not survive
abundantly in the healing tissue. Xuqian assumed that the
healing process in the transplantation group was promoted
by MSCs expression of cytokines with antiapoptotic func-
tions and related to extracellular matrix development, such
as intercellular adhesive factors, with better adhesion of the
retina to the RPE.
A recent case series of 7 human patients affected by
refractory and late-stage macular holes evaluated effects on
visual function and safety of MSC suspension and MSC-
Exos in combination with pars plana vitrectomy and gas
tamponade (SF6 or air in patients receiving exosomes) or
heavy silicon oil (in patients receiving cell suspension).
Silicon oil was employed in order to limit the dispersion of
the cell suspension, and patients were instructed to remain
(a) (b)
Figure 1: Histological findings revealing integration of mesenchymal stem cells at the level of the ganglion cell layer in the ischemic rat
retina. Mesenchymal stem cells were not able to migrate to the ganglion cell layer of nonischemic retina. VB� vitreous body; GCL� ganglion
cell layer; IPL� internal plexiform layer; INL� internal nuclear layer; EPL� external plexiform layer; ENL� external nuclear layer;
PRL� photoreceptor layer; RPE� retinal pigment epithelium; MSCs�mesenchymal stem cells.
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in supine position for 1 day. Silicon oil was then removed
with surgery in the two patients receiving the cell suspension
[91].
BCVA improvements were observed in five patients
presenting hole closure after surgery, with a mean post-
operative visual acuity of 20/110 (ranging from 20/160 to 20/
50). ,e complete hole closure was observed at 19 days after
surgery, by average (ranging from 3 days in a case receiving
MSCs suspension to 30 days in patients receiving intravitreal
MSC-Exos). ,e only patient who did not experience im-
provements in visual acuity was a woman with a 4-year
history of macular hole, which was already treated with
previous unsuccessful surgery. Nevertheless, she presented
hole closure at 1 month after pars plana vitrectomy with
intravitreal MSC-Exos, even if her BCVA remained un-
changed. Only one of the treated eyes did not presented a
macular hole closure after pars plana vitrectomy in com-
bination with phacoemulsification and intravitreal injection
of MSC-Exos, but its BCVA improved slightly (from 20/200
to 20/160) probably due to cataract removal. Among all the
patients included in the case series, reduction in central
scotoma was observed, with significant improvements in one
patient receiving 20 µg of MSC-Exos via intravitreal in-
jection in association with an air tamponade (in accordance
with an improvement in BCVA from 20/200 to 20/50).
In regard to adverse reactions, formation of fibrotic
epiretinal membrane due to proliferation of injected cells
occurred in one patient receiving MSCs in association with
pars plana vitrectomy and heavy silicon oil endotamponade.
,is fibrotic membrane was then removed through an ad-
ditional surgical procedure, and the pathological analysis
revealed the proliferation of fibroblast-like cells. In the
following 6 months, no recurrence of fibrotic membrane was
observed, and a decrease in central scotoma was reported.
Moreover, the first patient who underwent treatment with
50 μg of MSC-Exos presented signs of inflammation in the
anterior chamber, which was resolved 3 days after appli-
cation of steroid eyedrops. ,ereafter, MSC-Exos dose was
reduced to 20 μg without observation of other cases of
significant inflammation. All patients were subjected to a
follow-up period lasting between 0.5 and 3 years, without
evidence of side effects related to MSCs and MSC-Exos and
risk of teratoma development. However, limitations of this
preliminary study lie in the small number of patients and the
absence of a comparison with a control group, preventing
the assessment of the real therapeutic effects of MSCs and
MSC-Exos.
5. Discussion and Clinical Perspectives
Adjuvant surgical strategies, such as ILM inverted flap and
ILM insertion, have been adopted to improve outcomes in
refractory and large macular holes with successful ana-
tomical and visual outcomes [42, 92, 93].
However, these techniques are not without potential
problems, such the risk of direct damage to RPE. Moreover,
the heterogeneous characteristics of late stages and re-
fractory macular holes may prevent the actual assessment of
the effects of adjuvant procedures on postoperative results.
Among the few studies comparing different adjuvant
techniques, the analysis by Park et al. concluded that the
inverted flap technique resulted in better recovery of pho-
toreceptor layers with better functional outcomes, when
compared with ILM insertion [94].
Stem-cell therapy has emerged as a novel candidate
approach for the treatment of retinal degenerative diseases,
given their proven effects of neurogenesis, cell replacement,
reduced apoptosis, and modulation of inflammation and
immune responses [95, 96]. MSCs can be easily retrieved
from numerous adult tissues and can potentially differen-
tiate into RPE cells and photoreceptors, providing the
possibility of a retinal cell replacement therapy. Moreover,
protective effects of MSCs towards RGCs have been dem-
onstrated in an animal model of glaucoma [72].
In case of a macular hole, it is advisable to achieve the
contact between the retinal neural epithelium and the RPE,
in order to obtain hole closure [89]. ,ereafter, adherence of
the detached retinal edges to the RPE layer promotes cell
migration and proliferation of the overlying retina.
Xuqian et al. in their analysis on animal models con-
cluded that MSCs promote hole closure rate with accelerated
healing. Morphological histochemical and OCT observa-
tions showed significant differences between repair tissues in
eyes receiving MSCs and the reference group, which pre-
sented a typical fibrotic scarring [90].
Previous studies have demonstrated that MSCs promote
the expression of adhesive factors [97] and extracellular
matrix development [98]. In addition, several studies
demonstrated the antiapoptotic and protective effects of
MSCs, even at the gene level [99, 100]. In addition, MSCs
may exert their reparative effects on the retina through
material transfer, with improvement in visual function
[101, 102].
According to these findings, a possible rationale for
future stem-cell therapy may be developed, and failure of
macular hole surgery may be explained by long-term de-
tachment of neuroretina from the RPE layer.
In comparison to gene therapy, MSCs provide multiple
rescue pathways with a plurality of combined effects.
Moreover, in a previous paper published by our group, we
observed that the presence of a human retinal pigment
epithelial cell-line supernatant helped cells preserve the
typical MSC morphology [103]. ,erefore, we can hy-
pothesize that RPE can represent an ideal environment in
which MSCs can exert their function of cytokines and
neurotrophic factors release.
It has been reported that up to 44% of large macular
holes remain open after vitrectomy with ILM removal [26]
and repeated surgeries in case of failure are associated with a
lower closure rate compared with primary surgery [104].
In the only available pilot study, macular hole closure
was achieved in six of seven patients who underwentMSC or
MSC-Exo therapy, with five patients showing improvements
in BCVA. ,ese results suggest that MSCs and MSC-Exos
may contribute to hole closure and visual function recovery
[91]. MSCs and MSC-Exos can therefore be dedicated to
cases of refractory macular holes after first surgery, in which
satisfactory results are more difficult to achieve.
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Compared with cell suspensions, exosomes are easier to
employ, presenting lower immunogenicity and risk of
proliferation. It was reported that MSC-Exos have similar
protective effects towards the retina after laser-induced le-
sions and experimental model of uveitis [64, 105].
Since MSC-Exos do not tend to disperse in the vitreal
cavity after injection, heavy silicon tamponades and patient
positioning may not be relevant to promote their effects.
However, the mechanism of MSC-Exo therapy is still not
fully understood. It has been suggested that miRNAs carried
by MSC-Exos promote neurogenesis and functional re-
covery [106].
Another issue that must be addressed in larger trials is
toxicity of MSCs or MSC-Exo in the treatment of retinal
diseases. Among the existing clinical trials, three patients
were affected by severe bilateral vision loss after receiving
intravitreal injections of autologous adipose tissue derived
stem cells, due to severe vitreoretinal proliferation [87]
(probably occurred as a result of transformation of injected
cells in myofibroblasts-like cells). According to these find-
ings, MSC-Exo therapy may be safer than cell suspension,
since cell proliferation is less likely to occur.
Finally, as of today, there is no standardized number and
volume for cell injection into the retina. Current clinical
trials have injected from 1.68×104 to 3.4×106 cells in a
100–150 μl suspension, but the exact quantity needed still
remains to be discovered.
6. Conclusions
,e application of mesenchymal stem cells as an adjuvant
treatment for refractory and late-stage macular holes can be
considered as a promising perspective, in the light of the
recent functional and anatomic outcomes in both animal
and human trials. Combination of pars plana vitrectomy
and MSCs injections or MSCs exosomes application seems
feasible, but the evidence regarding their safety needs to be
expanded. Nevertheless, autologous mesenchymal stem
cells can be extracted from the same patient, which can act
both as the donor and the receiving subject, lowering re-
jection rates and immunological reactions. Furthermore,
repeated injections can be performed, if needed. ,e
beneficial effects of MSCs suspensions and exosomes lie in
their neuroprotective properties and in the facilitation of
macular hole adhesion to the RPE, which promotes healing
and closure. ,ese aspects can lead to an effective visual
rehabilitation in cases destined to poor results with simple
surgery (even if hole closure is achieved). However, MSCs
application at the retinal level can lead to unwanted dif-
ferentiation of transplanted cells with onset of vitreoretinal
proliferation, and the presence of preexisting tumors whose
growth may be promoted by immunosuppression provided
by MSCs represents an important contraindication [107].
Autologous MSCs can be considered safe in terms of
immunogenicity and de-novo malignancy development
[108]. Finally, long-term clinical trials featuring control
groups are still required in order to compare the efficacy of
MSCs applications with pars plana vitrectomy and other
adjuvant techniques.
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